Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AZTA Stock Summary
Top 10 Correlated ETFs
AZTA
In the News
Azenta, Inc. (AZTA) Q1 2024 Earnings Call Transcript
Azenta, Inc. (AZTA) Q1 2024 Earnings Call Transcript
5 medical stocks growing earnings by triple digits
While most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in their earnings calls, the reality is that the fundamentals now favor other (safer) areas of the economy.
Final Trade: DISH, GLD, EWJ and AZTA
The final trades of the day with the 'Fast Money' traders.
3 Stocks to Watch After Impressive Earnings Beats
In a somewhat quiet earnings lineup this week, several stocks stand out after posting strong quarterly results on Monday.
Azenta, Inc. (AZTA) Q4 2023 Earnings Call Transcript
Azenta, Inc. (NASDAQ:AZTA ) Q4 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Sara Silverman - Head of IR Steve Schwartz - President and CEO Herman Cueto - CFO Conference Call Participants David Saxon - Needham Jacob Johnson - Stephens Andrew Cooper - Raymond James Paul Knight - KeyBanc Vijay Kumar - Evercore ISI Yuan Zhi - B. Riley Operator Thank you, and welcome to the Azenta Q4 2023 Financial Results.
Azenta shares jump on Q4 results, buyback plans
Shares of Azenta Inc. AZTA, +0.59% jumped 11.9% after hours on Monday after the life-sciences company reported fourth-quarter results that beat expectations and announced plans to buy back an extra $500 million in stock in fiscal 2024. The company — whose products and services help researchers store, handle and process chemical and biological samples — reported net income of $3.4 million, or 6 cents a share, compared with a loss of $20.8 million, or 28 cents a share, in the same quarter last year.
Azenta: Life Science Play Suffers A Bad Diagnosis
Azenta, Inc., formerly Brooks Automation, sold its semiconductor business and subsequently became a pure play life science business. Azenta's shares have declined significantly and its valuation is still supported by net cash holdings. However, Azenta is not profitable, making it difficult to be optimistic about its shares.
You Can't Control Activist Investors, but You Can Control What You Do About Them
Having activist investors at a company can lead to big changes. Azenta is dealing with an activist's call for better performance as it puts a giant cash hoard to work.
Activist Politan Capital engages with Azenta. Here's how the firm may boost shareholder value
Azenta is sitting on a pile of cash, and shareholders will want to know the company's plans for the money.
Azenta to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
BURLINGTON, Mass. , Sept. 8, 2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY, on Wednesday, September 13, 2023, which includes a presentation beginning at 2:55 pm ET.
AZTA Financial details
AZTA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-09-30
Metric | History | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 10.86 | 12.2 | 6.92 | 7.42 | 10.04 | |
Net income per share | 0.14 | 0.88 | -0.39 | -0.15 | -0.22 | |
Operating cash flow per share | 1.26 | 0.51 | 2.02 | -6.22 | 0.26 | |
Free cash flow per share | 0.93 | -0.03 | 1.31 | -7.26 | -0.33 | |
Cash per share | 4.66 | 4.02 | 3.06 | 20.96 | 15.36 | |
Book value per share | 15.83 | 16.5 | 17.85 | 44.91 | 38.25 | |
Tangible book value per share | 5.55 | 6.71 | 9.02 | 35.67 | 21.97 | |
Share holders equity per share | 15.83 | 16.5 | 17.85 | 44.91 | 38.25 | |
Interest debt per share | 1.02 | 1.16 | 3.3 | 0.81 | 1.07 | |
Market cap | 2.67B | 3.4B | 7.6B | 3.21B | 3.33B | |
Enterprise value | 2.42B | 3.19B | 7.46B | 2.6B | 2.71B | |
P/E ratio | 269.55 | 52.47 | -263.17 | -284.43 | -233.24 | |
Price to sales ratio | 3.41 | 3.79 | 14.79 | 5.78 | 5 | |
POCF ratio | 29.33 | 89.86 | 50.7 | -6.89 | 190.12 | |
PFCF ratio | 39.77 | -1.65K | 78.28 | -5.91 | -151.52 | |
P/B Ratio | 2.34 | 2.8 | 5.73 | 0.95 | 1.31 | |
PTB ratio | 2.34 | 2.8 | 5.73 | 0.95 | 1.31 | |
EV to sales | 3.09 | 3.55 | 14.53 | 4.68 | 4.07 | |
Enterprise value over EBITDA | 23.48 | 22.03 | 397.35 | 52.34 | 65.73 | |
EV to operating cash flow | 26.57 | 84.23 | 49.81 | -5.58 | 154.76 | |
EV to free cash flow | 36.03 | -1.55K | 76.91 | -4.79 | -123.34 | |
Earnings yield | 0 | 0.02 | 0 | 0 | 0 | |
Free cash flow yield | 0.03 | 0 | 0.01 | -0.17 | -0.01 | |
Debt to equity | 0.04 | 0.07 | 0.18 | 0.02 | 0.03 | |
Debt to assets | 0.03 | 0.05 | 0.13 | 0.02 | 0.02 | |
Net debt to EBITDA | -2.43 | -1.47 | -7.06 | -12.25 | -15.02 | |
Current ratio | 2.37 | 3.08 | 2.25 | 10.67 | 6.73 | |
Interest coverage | 2.09 | 26.65 | -22.85 | -0.87 | 0 | |
Income quality | 0.21 | 0.58 | 1.35 | -0.22 | -1.23 | |
Dividend Yield | 0.01 | 0.01 | 0 | 0 | 0 | |
Payout ratio | 2.92 | 0.46 | -1.03 | -0.66 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.07 | 0.07 | 0.04 | 0.05 | 0.05 | |
Intangibles to total assets | 0.49 | 0.46 | 0.36 | 0.19 | 0.37 | |
Capex to operating cash flow | -0.26 | -1.05 | -0.35 | 0.17 | -2.25 | |
Capex to revenue | -0.03 | -0.04 | -0.1 | -0.14 | -0.06 | |
Capex to depreciation | -0.44 | -0.61 | -0.81 | -1.44 | -0.46 | |
Stock based compensation to revenue | 0.03 | 0.02 | 0.05 | 0.02 | 0.01 | |
Graham number | 6.99 | 18.09 | 12.5 | 12.34 | 13.61 | |
ROIC | 0.04 | 0.05 | -0.02 | 0 | -0.01 | |
Return on tangible assets | 0.01 | 0.08 | -0.02 | 0 | -0.01 | |
Graham Net | 1.84 | 2.02 | -1.97 | 18.46 | 12.8 | |
Working capital | 375.21M | 438.34M | 432.28M | 2.23B | 1.21B | |
Tangible asset value | 399.52M | 493.75M | 669.44M | 2.67B | 1.46B | |
Net current asset value | 270.44M | 303.94M | 283.19M | 2.11B | 1.07B | |
Invested capital | 0.04 | 0.07 | 0.18 | 0.02 | 0.03 | |
Average receivables | 146.3M | 177.47M | 154.08M | 141.82M | 160.15M | |
Average payables | 57.66M | 60.6M | 52.06M | 40.51M | 37.23M | |
Average inventory | 98.22M | 107.14M | 87.62M | 72.97M | 106.87M | |
Days sales outstanding | 77.8 | 76.59 | 85.18 | 107.6 | 85.91 | |
Days payables outstanding | 46.64 | 43.58 | 57.29 | 47.04 | 32.51 | |
Days of inventory on hand | 78.04 | 81.03 | 81.68 | 104.11 | 116.42 | |
Receivables turnover | 4.69 | 4.77 | 4.29 | 3.39 | 4.25 | |
Payables turnover | 7.83 | 8.38 | 6.37 | 7.76 | 11.23 | |
Inventory turnover | 4.68 | 4.5 | 4.47 | 3.51 | 3.14 | |
ROE | 0.01 | 0.05 | -0.02 | 0 | -0.01 | |
Capex per share | -0.33 | -0.54 | -0.71 | -1.03 | -0.6 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q1
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.46 | 2.24 | 2.62 | 2.89 | 2.72 | |
Net income per share | -0.15 | -0.03 | -0.02 | 0.06 | -0.28 | |
Operating cash flow per share | -0.37 | -0.18 | 0.26 | 0.67 | 0.47 | |
Free cash flow per share | -0.55 | -0.32 | 0.15 | 0.5 | 0.26 | |
Cash per share | 15.59 | 17.8 | 17.72 | 17.08 | 17.35 | |
Book value per share | 39.58 | 43.62 | 42.94 | 42.52 | 43.09 | |
Tangible book value per share | 24.58 | 26.83 | 25.5 | 24.43 | 23.86 | |
Share holders equity per share | 39.58 | 43.62 | 42.94 | 42.52 | 43.09 | |
Interest debt per share | 0.83 | 1.05 | 1.01 | 1.08 | 1.41 | |
Market cap | 4.22B | 2.96B | 2.96B | 2.99B | 3.69B | |
Enterprise value | 3.67B | 2.35B | 2.29B | 2.37B | 3.06B | |
P/E ratio | -93.98 | -371.83 | -503.57 | 221.59 | -58.73 | |
Price to sales ratio | 23.68 | 19.95 | 17.84 | 17.36 | 23.94 | |
POCF ratio | -156.31 | -243.73 | 176.8 | 74.95 | 139.76 | |
PFCF ratio | -105.95 | -140.93 | 320.63 | 100.74 | 254.55 | |
P/B Ratio | 1.47 | 1.02 | 1.09 | 1.18 | 1.51 | |
PTB ratio | 1.47 | 1.02 | 1.09 | 1.18 | 1.51 | |
EV to sales | 20.56 | 15.84 | 13.8 | 13.77 | 19.81 | |
Enterprise value over EBITDA | -255.23 | -112.51 | 134.35 | 137.1 | -1.19K | |
EV to operating cash flow | -135.74 | -193.5 | 136.7 | 59.46 | 115.68 | |
EV to free cash flow | -92.01 | -111.89 | 247.91 | 79.92 | 210.69 | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | -0.01 | -0.01 | 0 | 0.01 | 0 | |
Debt to equity | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
Debt to assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | |
Net debt to EBITDA | 38.68 | 29.2 | -39.41 | -35.73 | 247.55 | |
Current ratio | 6.51 | 7.46 | 7.42 | 6.73 | 5.87 | |
Interest coverage | -609.84 | -8.78 | 0 | 5.03 | 0 | |
Income quality | 2.4 | 2.47 | -11.39 | 11.83 | -1.68 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.04 | 0.06 | 0.05 | 0.05 | 0.06 | |
Intangibles to total assets | 0.33 | 0.34 | 0.36 | 0.37 | 0.39 | |
Capex to operating cash flow | 0.48 | 0.73 | -0.45 | -0.26 | -0.45 | |
Capex to revenue | -0.07 | -0.06 | -0.05 | -0.06 | -0.08 | |
Capex to depreciation | -0.64 | -0.4 | -0.35 | -0.46 | -0.55 | |
Stock based compensation to revenue | 0.01 | 0.03 | 0.02 | 0 | 0.02 | |
Graham number | 11.74 | 5.43 | 4.73 | 7.36 | 16.4 | |
ROIC | -0.01 | 0 | 0 | 0 | -0.01 | |
Return on tangible assets | -0.01 | 0 | 0 | 0 | -0.01 | |
Graham Net | 12.88 | 15.49 | 15.31 | 14.23 | 13.83 | |
Working capital | 1.37B | 1.37B | 1.31B | 1.21B | 1.15B | |
Tangible asset value | 1.78B | 1.78B | 1.62B | 1.46B | 1.35B | |
Net current asset value | 1.2B | 1.23B | 1.16B | 1.07B | 1B | |
Invested capital | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
Average receivables | 182.84M | 184.94M | 165.49M | 159.78M | 156.23M | |
Average payables | 46.96M | 50.28M | 41.65M | 36.89M | 38.02M | |
Average inventory | 115.74M | 148.33M | 146.41M | 135.15M | 127.69M | |
Days sales outstanding | 101.88 | 101.86 | 88.41 | 81.74 | 90.94 | |
Days payables outstanding | 47.59 | 42.85 | 34.91 | 30.88 | 39.02 | |
Days of inventory on hand | 125.69 | 142.55 | 130.58 | 110.6 | 123.34 | |
Receivables turnover | 0.88 | 0.88 | 1.02 | 1.1 | 0.99 | |
Payables turnover | 1.89 | 2.1 | 2.58 | 2.91 | 2.31 | |
Inventory turnover | 0.72 | 0.63 | 0.69 | 0.81 | 0.73 | |
ROE | 0 | 0 | 0 | 0 | -0.01 | |
Capex per share | -0.18 | -0.13 | -0.12 | -0.17 | -0.21 |
AZTA Frequently Asked Questions
What is Azenta, Inc. stock symbol ?
Azenta, Inc. is a US stock , located in Chelmsford of Ma and trading under the symbol AZTA
Is Azenta, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $70. The lowest prediction is $62 and the highest is $78
What is AZTA stock prediction ?
What is Azenta, Inc. stock quote today ?
Azenta, Inc. stock price is $60.28 today.
Is Azenta, Inc. stock public?
Yes, Azenta, Inc. is a publicly traded company.